AvidBiotics Corp. announced on Wednesday that it received a patent from the U.S. Patent and Trademark Office for its potent bactericidal proteins that target and kill Clostridium difficile.
The deadly proteins were specifically designed to attack C. difficile without causing harm to healthy gut microbiota. The invention provides a practical method of eliminating the bacteria without causing greater harm to the person or animal with the infection.
"C. difficile infections represent one of the most threatening and rapidly growing hospital- and more recently, community-acquired bacterial infections," AvidBiotics CEO David W. Martin said. "Treatment of these infections with traditional antibiotics kills protective gut bacteria, which then enables a smoldering C. difficile infection to quickly expand in the gut, causing life-threatening diarrhea and colitis. Even after initial successful treatment with antibiotics, C. difficile infection recurs at a frightening rate. Diffocins, successfully developed for humans, would offer the advantage of a drug for both prevention and treatment of C. difficile infections without the unintended collateral damage to the microbiota, which inevitably occurs with conventional antibiotics."
Martin said the company will file an Investigational New Drug application with the U.S. Food and Drug Administration in 2015.
The patent, number 8,673,291, was awarded for the modified diffocin and the methods of manufacturing the proteins.
"This patent issuance marks an important milestone in the development of our Avidocin protein antibacterial platform, which enables the highly targeted killing of specific bacteria without collateral damage to off-target species in the human microbiome," AvidBiotics President James Knighton said. "In addition to this selective anti-C. difficile Avidocin protein, we have tailored other Avidocin proteins against a wide range of other bacterial pathogens important in human health, such as Klebsiella, E. coli, Salmonella, and Acinetobacter."